ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics Third Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, November 5 2025.
Adma Biologics Inc. (ADMA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sachem Head Capital Scott Ferguson | 8,960,000 | $131,353,600 | 3.71% | |
| 2. | Renaissance Technologies Jim Simons | 2,770,442 | $40,614,680 | -12% | 0.05% |
| 3. | Caligan Partners David Johnson | 2,636,609 | $38,652,688 | 5.06% | |
| 4. | Ranger Investment Management Conrad Doenges (Cio) | 2,340,730 | $34,315,102 | -3% | 2.39% |
| 5. | Citadel Investment Group Ken Griffin | 2,119,162 | $31,066,915 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.71 | 130,000 | $482,144.00 | 443,265 | 2023-08-30 | Filing | |
| $3.90 | 25,000 | $97,500.00 | 277,401 | 2023-08-24 | Filing | |
| $2.86 | 6,993 | $19,999.98 | 1,034,825 | 2022-12-09 | Filing | |
| $2.86 | 14,982 | $42,848.52 | 1,143,426 | 2022-12-09 | Filing | |
| $2.86 | 14,983 | $42,851.38 | 2,203,708 | 2022-12-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.79 | 6,000 | $118,740.00 | 2,007,850 | 2025-12-15 | Filing | |
| $19.79 | 15,000 | $296,850.00 | 2,013,850 | 2025-12-15 | Filing | |
| $16.00 | 6,000 | $96,000.00 | 2,013,850 | 2025-11-19 | Filing | |
| $16.00 | 15,000 | $240,000.00 | 2,019,850 | 2025-11-19 | Filing | |
| $16.00 | 6,000 | $96,000.00 | 2,019,850 | 2025-10-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 35,631,714 | $522,360,930 | 0.01% | |
| 2. | 20,974,996 | $307,493,442 | 0% | |
| 3. | 13,561,645 | $198,813,716 | 0.01% | |
| 4. | 12,505,478 | $183,330,309 | 0.03% | |
| 5. | 2,838,143 | $104,304,510 | 0.03% |
News See All
Renaissance Small Cap Growth Strategy Added ADMA Biologics (ADMA) to Its Portfolio in Q2
Renaissance Investment Management, an investment management company, released its Q2 2025 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here.
ADMA Biologics, Inc. (ADMA): A Bull Case Theory
We came across a bullish thesis on ADMA Biologics, Inc. on Archive Invest’s Substack by Felix. In this article, we will summarize the bulls’ thesis on ADMA.
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the ADMA Biologics Second Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, August 6, 2025.
Heavy Insider Selling at ADMA Biologics Despite Earnings Strength
Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies.
13 Best Low Risk High Growth Stocks to Buy
The current market is witnessing political chess moves, which are also affecting policy changes.
ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios
ADMA Biologics fell by 14.7 percent week-on-week, closing Friday at $17.74 versus the $20.81 on June 13, as investors took path from three of its executives’ recent disposition of shares in the company...
ADMA Biologics (ADMA) Drops for 5th Consecutive Day - Here's Why
While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.
ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.